Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: Incidence, severity, and risk factors

Journal of Orthopaedic Science

Volumn 15, Issue 1, 2010, Pages 104-111

  Tajino, Takahiro ^a   Kikuchi, Shin Ichi ^a   Yamada, Hitoshi ^a   Takeda, Akira ^b   Konno, Shin Ichi ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b Southern Tohoku General Hospital and Southern Tohoku Research Institute for Neuroscience   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BICARBONATE; CARBOPLATIN; CHLORPROMAZINE; CISPLATIN; DACARBAZINE; DEXAMETHASONE; DIAZEPAM; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METOCLOPRAMIDE; MIDAZOLAM; SEROTONIN 3 ANTAGONIST; THERARUBICIN; UNCLASSIFIED DRUG; VINCRISTINE; VINDESINE;

ADOLESCENT; ADULT; AGED; AGITATION; ARTICLE; BRAIN DISEASE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHILD; CONFUSION; CONTINUOUS INFUSION; CONTROLLED STUDY; CONVULSION; DISEASE SEVERITY; DROWSINESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; INCIDENCE; INVOLUNTARY COMMITMENT; JAPANESE; MAJOR CLINICAL STUDY; MALE; METABOLIC ACIDOSIS; MOOD; MOOD CHANGE; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL SARCOMA; NAUSEA; NEUROLOGIC DISEASE; OSTEOSARCOMA; PERSONALITY DISORDER; PSYCHOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SARCOMA; SCHOOL CHILD; SEIZURE; SENSORY NEUROPATHY; SIDE EFFECT; SOFT TISSUE SARCOMA; SOMNOLENCE; SYMPTOM; TREATMENT OUTCOME; TUMOR LOCALIZATION;

EID: 77249093710     PISSN: 09492658     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00776-009-1431-y     Document Type: Article

References (30)

1. B.M.J. Cantwell A.L. Harris 1985 Ifosfamide/mesna and encephalopathy Lancet 1 752 10.1016/S0140-6736(85)91288-7 2858016 1:STN:280: DyaL2M7js1Oiug%3D%3D
2. M.E. Heim R. Fiene E. Schick E. Wolpert W. Queisser 1981 Central nervous side effects following ifosfamide monotherapy of advanced renal carcinoma J Cancer Res Clin Oncol 100 113 116 10.1007/BF00405909 7240342 1:STN:280:DyaL3M3hsFyjtA%3D%3D (Pubitemid 11156553)
3. S.R. Patel S. Vadhan-Raj N. Papadopolous C. Plager M.A. Burgess C. Hays, et al. 1997 High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies - dose-response and schedule dependence J Clin Oncol 15 2378 2384 9196153 1:CAS:528:DyaK2sXkt1ersb4%3D
4. E. Salloum F. Flamant M. Ghosn 1987 Irreversible encephalopathy with ifosfamide/mesna J Clin Oncol 5 1303 1304 3114437 1:STN:280:DyaL2szhtVGkug%3D%3D
5. C.A. Meanwell J.J. Mould G. Blackledge F.G. Lawton N.S.A. Stuart J. Kavanagh, et al. 1986 Phase II study of ifosfamide in cervical cancer Cancer Treat Rep 70 727 730 3089596 1:STN:280:DyaL283ntFyjtw%3D%3D
6. O. Merimsky I. Reider-Groswasser N. Wigler S. Chaitchik 1992 Encephalopathy in ifosfamide-treated patients Acta Neurol Scand 86 521 525 10.1111/j.1600-0404.1992.tb05136.x 1481635 1:STN:280:DyaK3s7islyjtg%3D%3D
7. A. Verdeguer V. Castel C. Esquembre J. Ferris J.M. Fernandez J.G. Ruiz 1989 Fatal encephalopathy with ifosfamide/mesna Pediatr Hematol Oncol 6 383 385 10.3109/08880018909034311 2518327 1:STN:280:DyaK3czms1Cjug%3D%3D
8. M.P. Goren R.K. Wright C.B. Pratt F.E. Pell 1986 Dechloroethylation of ifosfamide and neurotoxicity Lancet 2 1219 1220 10.1016/S0140-6736(86)92227-0 2877353 1:STN:280:DyaL2s%2FjvVGjug%3D%3D
9. A. Küpfer C. Aeschlimann T. Cerny 1996 Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy Eur J Clin Pharmacol 50 249 252 10.1007/s002280050102 8803513 (Pubitemid 26188273)
10. J.L. Alonso Y. Nieto J.A. López M. Martín E. Díaz-Rubio 1996 Ifosfamide encephalopathy and methylene-blue: a case report Ann Oncol 7 643 644 8879383 1:STN:280:DyaK2s%2FjtlOhtw%3D%3D
11. M.H. Cohen P.J. Creaven F. Tejada H. Hansen F. Muggia A. Mittelman, et al. 1975 Phase I clinical trial of isophosphamide (NSC-109724) Cancer Chemother Rep 59 751 755 1100226 1:STN:280:DyaE28%2FitVGrtA%3D%3D
12. C. Rieger M. Fiegl J. Tischer H. Ostermann X. Schiel 2004 Incidence and severity of ifosfamide-induced encephalopathy Anticancer Drugs 15 347 350 10.1097/00001813-200404000-00006 15057138 1:CAS:528:DC%2BD2cXjvVOrsbY%3D (Pubitemid 38526758)
13. J.J. Van Dyk H.C. Falkson A.M. Van der Merwe G. Falkson 1972 Unexpected toxicity in patients treated with iphosphamide Cancer Res 32 921 924 4552918
14. M.M. Danesh C.M. De Giorgio S.R. Beydoun R.A. Kemp 1989 Ifosfamide encephalopathy J Toxicol Clin Toxicol 27 293 298 10.3109/15563658908994426 2600992 1:STN:280:DyaK3c%2Fps1ahsg%3D%3D
15. T. Ajithkumar C. Parkinson F. Shamshad P. Murray 2007 Ifosfamide encephalopathy Clin Oncol (R Coll Radiol) 19 108 114 1:STN:280: DC%2BD2s7lsFGhtQ%3D%3D
16. T.P. Warrington J.M. Bostwick 2006 Psychiatric adverse effects of corticosteroids Mayo Clin Proc 81 1361 1367 10.4065/81.10.1361 17036562 1:CAS:528:DC%2BD28XhtFert7bN
17. Gastrointestinal Tumor Study Group. 1989 Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma Cancer 64 2010 2013 10.1002/1097-0142(19891115)64:10<2010::AID-CNCR2820641007>3.0.CO;2-O
18. K.H. Antman L. Ryan A. Elias D. Sherman H.E. Grier 1989 Response to ifosfamide and mesna: 124 previously treated patients with metastatic or resectable sarcoma J Clin Oncol 7 126 131 2491883 1:STN:280: DyaL1M%2FotVOqtA%3D%3D
19. N.R. Anderson D.S. Tandon 1991 Ifosfamide extrapyramidal neurotoxicity Cancer 68 72 75 10.1002/1097-0142(19910701)68:1<72::AID-CNCR2820680114>3. 0.CO;2-# 2049756 1:STN:280:DyaK3M3ms1agsw%3D%3D
20. K.H. Antman A. Elias L. Ryan 1990 Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules Semin Oncol 17 suppl4 68 73 2110386 1:STN:280:DyaK3c3jvFGrtA%3D%3D
21. J.P. Curtin P.P. Koonings M. Gutierrez J.B. Schlaerth C.P. Morrow 1991 Ifosfamide-induced neurotoxicity Gynecol Oncol 42 193 196 10.1016/0090-8258(91) 90344-5 1955179 1:STN:280:DyaK38%2FmsValtw%3D%3D
22. C.B. Pratt A.A. Green M.E. Horowitz W.H. Meyer E. Etcubanas E. Douglass, et al. 1986 Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna J Clin Oncol 4 1253 1261 3090210 1:STN:280:DyaL283otVKhtg%3D%3D
23. C.A. Meanwell A.E. Blake K.A. Kelly L. Honigsberger G. Blackledge 1986 Prediction of ifosfamide/mesna associated encephalopathy Eur J Cancer Clin Oncol 22 815 819 10.1016/0277-5379(86)90368-8 3095121 1:STN:280: DyaL2s%2FjtVCltA%3D%3D (Pubitemid 16071303)
24. M.P. Goren R.K. Wright C.B. Pratt M.E. Horowitz R.K. Dodge M.J. Viar, et al. 1987 Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum (II) therapy Cancer Res 47 1457 1460 3815347 1:CAS:528:DyaL2sXhsV2jurY%3D
25. C.B. Pratt M.P. Goren W.H. Meyer B. Singh R.K. Dodge 1990 Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumor J Clin Oncol 8 1399 1401 2380760 1:STN:280:DyaK3czjvFWjsw%3D%3D
26. M.J. Lind J.M. Margison T. Cerny N. Thatcher P.M. Wilkinson 1989 Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma Cancer Res 49 753 757 2910494 1:STN:280:DyaL1M%2FovFKntA%3D%3D
27. H. Karin B. Carsten H.P. Lipp 2005 Accurate measurement of individual glomerular filtration rate in cancer patients: an ongoing challenge J Cancer Res Clin Oncol 131 559 567 10.1007/s00432-005-0679-7 (Pubitemid 41558547)
28. G. Daugaard 1990 Cisplatin nephrotoxicity: experimental and clinical studies Dan Med Bull 37 1 2 2178884 1:STN:280:DyaK3c7otlCrsQ%3D%3D
29. J. Pelgrims F. De Vos J. Van den Brande D. Schrijvers A. Prové J.B. Vermorken 2000 Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature Br J Cancer 82 291 294 10.1054/bjoc.1999.0917 10646879 1:CAS:528:DC%2BD3cXpt12jtQ%3D%3D
30. J.M. Buesa P. Garcia-Teijido R. Losa J. Fra 2003 Treatment of ifosfamide encephalopathy with intravenous thiamin Clin Cancer Res 9 4636 4637 14555540 1:CAS:528:DC%2BD3sXotVShtL8%3D